Analysis of the Global Oncology Drug Delivery Market : Future Impact of Emerging Technologies

Analysis of the Global Oncology Drug Delivery Market : Future Impact of Emerging Technologies

  • February 2015 •
  • 85 pages •
  • Report ID: 2750950 •
  • Format: PDF

Analysis contained in this research service is based on the following:
• Information collected through discussions with market participants and from secondary sources, including pharmaceutical companies and medical devices companies involved in drug delivery systems as well as other Websites and credible sources.
• Public announcements and plans by key market leaders, suppliers, new entrants, and others.
• Frost & Sullivan’s published research and market and technology expertise.
All market figures and shares listed in the research are Frost & Sullivan's assessment based on its research.
For Market Engineering research, Frost & Sullivan utilises tried and tested marketing techniques to provide structure to the research and an easy format to compare results across different countries and markets. This project was carried out using primary (telephone) and secondary (published and online material) research as the principle methods of data gathering. The focus of the interviews for this project was primarily the respondent types outlined below.
• Industry participants
• End-users
• Key regulatory bodies
• Frost & Sullivan published research services
• Decision support databases
• Country industry forecasts
• Annual reports published by companies

Key Findings

•The total global oncology drug delivery market (or oncolytics market) was worth $ x billion in 2013 and has been growing at an annual rate of x %. The market was estimated at $ x billion in 2014 (including drug delivery systems for cancer therapy and cancer pain).
•The oral oncology drug delivery segment accounted for x % of the total market and is expected to continue its strong growth in 2015.
•The United States accounted for the largest revenue share in the total market with $ x billion in 2013.
•An estimated x drugs for treating or preventing cancer are in the pipeline globally. Of these, about x % have the potential to be first-in-class treatments if they successfully reach Phase 3 trials. Currently, US biopharmaceutical companies have an estimated x drugs and vaccines for treating or preventing cancer in clinical trials or awaiting Food and Drug Administration (FDA) review.
•Traditionally, intravenous (IV) and injected treatments were considered the primary methods of chemotherapy delivery; these methods are covered under a health plan’s medical benefit, where the patient is only required to co-pay. In addition, the prescribers considered that the efficacy (bio-availability) of drugs is better with injectables.
•As patient-administered (self-injectable and oral drug delivery systems) anti-cancer medications are often covered under a health plan’s prescription benefit, many patients end up paying out-of-pocket for the high and unmanageable co-pays; in some cases, this results in spends upwards of hundreds or thousands of dollars per month. As a result, it has been estimated that more than x % of the patients in the United States choose not to fill their initial prescriptions for oral anti-cancer medications due to the high rates of cost-sharing and opt for injectables instead.
•Currently, the injectable segment leads the oncology drug delivery market; however, nano-particles (micro-needles, patches, and orals) is expected to lead the market in the future.
•F. Hoffmann-La Roche AG, Novartis AG, and Celgene Corporation are the top three participants, collectively accounting for more than x % of the total market, followed by Johnson & Johnson, AstraZeneca Plc, Bristol-Myers Squibb, and Pfizer, Inc.
•The Essemblix Drug Development Platform, nanodaises, nano-cocoons, and micro bubble liposome particle delivery are some of the potential technologies that can prove to be game changers in the future.

Key Questions This Study Will Answer

Is the market growing? How long will it continue to grow, and at what rate?
Who are the key competitors in this market?
What are the major drivers and restraints in this market?
Which is the most attractive segment in the total oncology drug delivery market?
What are the upcoming technologies in the oncology drug delivery market?